Articles

FOIA, the Privacy Act, the Telemarketing and Consumer Fraud and Abuse Prevention Act, Telemarketing Sales Rule, FTC Act, Sarbanes-Oxley Act, Human Subjects Rule

Michigan Governor Rick Snyder (R) signed H.B. 4314 into law as Public Act 58 of 2011 on June 14.

Texas governor, Rick Perry, has signed a new health bill, H.B. 300, into law that enforces new obligations in addition to the requirements of the HIPAA privacy rule. The law, which becomes effective September 1, 2012, provides an expansive definition of a covered entity and is likely to include non-covered entities under HIPAA, including survey researchers.

The Food and Drug Administration (FDA) has responded to MRA on our concerns regarding the confidentiality of marketing research data.

The Gramm-Leach-Bliley (GLB) Act is a federal law concerned, in part, with privacy and security of consumer financial information.

Maine’s Joint Standing Committee on Judiciary voted Friday to recommend the prompt repeal of the Prevent Predatory Marketing Practices against Minors Act, a law prohibiting the transfer of personal information regarding minors (under 18). The Marketing Research Association (MRA), which had filed comments with the Committee, applauded the legislators’ efforts and looks forward to working with them to craft a new, more carefully crafted law, which will not impede survey and opinion research.

The Marketing Research Association requested today that the Joint Standing Committee on Judiciary in Maine exempt survey and opinion research from their data transfer prohibitions. A new Maine law, the Prevent Predatory Marketing Practices against Minors Act, aimed at protecting minors in Maine under 18 years old, prohibits any transfer of their personally identifiable information, for any purpose, regardless of any parental consent.

A new Maine law aimed at protecting minors in Maine under 18 years of age prohibits any transfer of their personally identifiable information.

The United States District Court for the Northern District of Oklahoma ruled last week in State of Oklahoma v. Tyson Foods that the personal identification of respondents in survey research is confidential information.

Pharmaceutical marketing research and data analytics companies should not be required to assume responsibility for formal reporting of adverse events (AEs) uncovered during routine pharmaceutical marketing research and data analytics in the U.S. because: